CRA International (CRAI) is expected to report Q3 2026 revenue of $199.04 million and non-GAAP EPS of $2.07, as the stock trades near $200.94 against an average analyst price target of $245.00.
Investors are primarily focused on the company’s utilization rate, which reached a high of 77% in the prior-year period, as a signal of sustained demand for its high-value consulting services.
Recent performance has been bolstered by record growth in the Antitrust & Competition Economics practice and strategic headcount expansions in Life Sciences. Market sentiment remains optimistic following management’s upward revision of full-year 2026 guidance in the previous quarter, though margin pressure from talent acquisition costs remains a secondary concern.